{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:00:05Z","timestamp":1773504005386,"version":"3.50.1"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1999,9,1]],"date-time":"1999-09-01T00:00:00Z","timestamp":936144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1999,9,1]],"date-time":"1999-09-01T00:00:00Z","timestamp":936144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[1999,9]]},"DOI":"10.1007\/bf02906128","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T19:03:10Z","timestamp":1210359790000},"page":"166-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["The role of busulfan in bone marrow transplantation"],"prefix":"10.1007","volume":"16","author":[{"given":"M","family":"Hassan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[1999,9,1]]},"reference":[{"key":"BF02906128_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(53)90884-8","volume":"1","author":"A Haddow","year":"1953","unstructured":"Haddow A, Timmis G. Myleran in chronic myeloid leukemia.Lancet 1953;1: 207.","journal-title":"Lancet"},{"key":"BF02906128_CR2","first-page":"703","volume":"12","author":"DA Galton","year":"1969","unstructured":"Galton DA. The possibility of radical chemotherapy in chronic myelocytic leukemia.Semin Hematol 1969;12: 703\u2013709.","journal-title":"Semin Hematol"},{"key":"BF02906128_CR3","first-page":"323","volume":"6","author":"DA Galton","year":"1969","unstructured":"Galton DA. Chemotherapy of chronic myelocytic leukemia.Semin Hematol 1969;6: 323\u2013343.","journal-title":"Semin Hematol"},{"key":"BF02906128_CR4","first-page":"309","volume":"57","author":"CR Singer","year":"1984","unstructured":"Singer CR, McDonald GA, Douglas AS. Twenty-five year survival of chronic granulocytic leukaemia with spontaneous karyotype conversion.Br J Haematol 1984;57: 309\u2013313.","journal-title":"Br J Haematol"},{"key":"BF02906128_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev.me.24.020173.001433","volume":"24","author":"JE Sokal","year":"1973","unstructured":"Sokal JE. Current concepts in the treatment of chronic myelocytic leukemia.Annu Rev Med 1973;24: 281\u2013288.","journal-title":"Annu Rev Med"},{"key":"BF02906128_CR6","first-page":"412","volume":"69","author":"W Hunstein","year":"1974","unstructured":"Hunstein W. Therapeutic considerations in chronic myeloid leukemia.Med Klin 1974;69: 412\u2013416.","journal-title":"Med Klin"},{"key":"BF02906128_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1399-0004.1975.tb00323.x","volume":"7","author":"P Staven","year":"1975","unstructured":"Staven P, Hagen CVD, Vogt E, Sandnes K. Polycythemia vera treated with 32p and myleran: development of chronic granulocytic leukemia with chromosomal abnormalities in one patient.Clin Genet 1975;7: 227\u2013231.","journal-title":"Clin Genet"},{"key":"BF02906128_CR8","first-page":"1533","volume":"86","author":"P Ernst","year":"1971","unstructured":"Ernst P, Boye Nielsen J, Killman SE. Treatment of polycythemia vera.Nord Med 1971;86: 1533.","journal-title":"Nord Med"},{"key":"BF02906128_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2141.1982.tb03855.x","volume":"52","author":"I Brodsky","year":"1982","unstructured":"Brodsky I. Busulphan treatment of polycythaemia vera.Br J Haematol 1982;52: 1\u20136.","journal-title":"Br J Haematol"},{"key":"BF02906128_CR10","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/jnci\/59.1.61","volume":"59","author":"I Brodsky","year":"1977","unstructured":"Brodsky I, Fuscaldo AA, Erlick BJ, Fuscaldo KE. Effect of busulfan on oncornavirus-like activity in platelets and chromosomes in polycythemia vera and essential thrombocythemia.J Natl cancer Inst 1977;59: 61\u201367.","journal-title":"J Natl cancer Inst"},{"key":"BF02906128_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1365-2141.1986.tb02926.x","volume":"62","author":"JE Van de Pette","year":"1986","unstructured":"Van de Pette JEet al. Primary thrombocythaemia treated with busulphan.Br J Haematol 1986;62: 229\u2013237.","journal-title":"Br J Haematol"},{"key":"BF02906128_CR12","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/bmj.1.5644.638-a","volume":"1","author":"DJ Weatherall","year":"1969","unstructured":"Weatherall DJ, Galton DA, Kay HE. Busulphan and bone marrow depression.Br Med J 1969;1: 638.","journal-title":"Br Med J"},{"key":"BF02906128_CR13","first-page":"511","volume":"21","author":"OP Ganda","year":"1973","unstructured":"Ganda OP, Mangalik A. Delayed toxic effect of busulfan on the marrow.J Assoc Physicians India 1973;21: 511\u2013516.","journal-title":"J Assoc Physicians India"},{"key":"BF02906128_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0006-2952(58)90006-6","volume":"1","author":"L Elson","year":"1958","unstructured":"Elson L. The effect of Myleran (1\u22364-dimethanesulphonyloxybutane) and homologous compounds on the blood.Biochem Pharmacol 1958;1: 39.","journal-title":"Biochem Pharmacol"},{"key":"BF02906128_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/0027-5107(78)90201-4","volume":"56","author":"A Leonard","year":"1978","unstructured":"Leonard A, Leonard ED. Cytogenic effects of myleran in vivo on bone-marrow cells from male mice.Mutat Res 1978;56: 329\u2013333.","journal-title":"Mutat Res"},{"key":"BF02906128_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/1097-0142(197105)27:5<1074::AID-CNCR2820270511>3.0.CO;2-G","volume":"27","author":"RH Kirschner","year":"1971","unstructured":"Kirschner RH, Esterly JR. Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia.Cancer 1971;27: 1074\u20131080.","journal-title":"Cancer"},{"key":"BF02906128_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.7326\/0003-4819-77-6-977","volume":"77","author":"ECD Rosenow","year":"1972","unstructured":"Rosenow ECD. The spectrum of drug-induced pulmonary disease.Ann Intern Med 1972;77: 977\u2013999.","journal-title":"Ann Intern Med"},{"key":"BF02906128_CR18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1002\/1097-0142(19840215)53:4<954::AID-CNCR2820530422>3.0.CO;2-Q","volume":"53","author":"JP Aymard","year":"1984","unstructured":"Aymard JP, Gyger M, Lavallee R, Legresley LP, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung?Cancer 1984;53: 954\u2013956.","journal-title":"Cancer"},{"key":"BF02906128_CR19","first-page":"408","volume":"101","author":"WA Burns","year":"1970","unstructured":"Burns WA, McFarland W, Matthews MJ. Busulfan-induced pulmonary disease. Report of a case and review of the literature.Am Rev Respir Dis 1970;101: 408\u2013413.","journal-title":"Am Rev Respir Dis"},{"key":"BF02906128_CR20","first-page":"308","volume":"27","author":"H Koch","year":"1976","unstructured":"Koch H, Lesch R. [Busulfan lung. Pulmonary fibrosis caused by Myleran].Med Welt 1976;27: 308\u2013311.","journal-title":"Med Welt"},{"key":"BF02906128_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/bmj.1.5794.218","volume":"1","author":"MP Ravindranathan","year":"1972","unstructured":"Ravindranathan MP, Paul VJ, Kuriakose ET. Cataract after busulphan treatment.Br Med J 1972;1: 218\u2013219.","journal-title":"Br Med J"},{"key":"BF02906128_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.0954-6820.1972.tb04789.x","volume":"192","author":"S Dahlgren","year":"1972","unstructured":"Dahlgren S, Holm G, Svanborg N, Watz R. Clinical and morphological side-effects of busulfan (Myleran) treatment.Acta Med Scand 1972;192: 129\u2013135.","journal-title":"Acta Med Scand"},{"key":"BF02906128_CR23","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","volume":"309","author":"GW Santos","year":"1983","unstructured":"Santos GWet al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.N Engl J Med 1983;309: 1347\u20131353.","journal-title":"N Engl J Med"},{"key":"BF02906128_CR24","first-page":"711","volume":"68","author":"C Lu","year":"1984","unstructured":"Lu C, Braine HG, Kaizer H, Saral R, Tutschka PJ, Santos GW. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.Cancer Treat Rep 1984;68: 711\u2013717.","journal-title":"Cancer Treat Rep"},{"key":"BF02906128_CR25","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1182\/blood.V73.8.2209.2209","volume":"73","author":"RB Geller","year":"1989","unstructured":"Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB,et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia.Blood 1989;73: 2209\u20132218.","journal-title":"Blood"},{"key":"BF02906128_CR26","first-page":"445","volume":"10","author":"TJ Nevill","year":"1992","unstructured":"Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH,et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT.Bone Marrow Transplant 1992;10: 445\u2013450.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR27","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","volume":"89","author":"JT Slattery","year":"1997","unstructured":"Slattery JT, Clift RA, Buckner CD, Radich J, Storer B,et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.Blood 1997;89: 3055\u20133060.","journal-title":"Blood"},{"key":"BF02906128_CR28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/sj.bmt.1700733","volume":"19","author":"M de Magalhaes-Silverman","year":"1997","unstructured":"de Magalhaes-Silverman M, Lister J, Rybka W, Wilson J, Ball E. Busulfan and cyclophosphamide (BU\/CY2) as preparative regimen for patients with lymphoma.Bone Marrow Transplant 1997;19: 777\u2013781.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/sj.bmt.1700662","volume":"19","author":"AA Maschan","year":"1997","unstructured":"Maschan AAet al. Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation.Bone Marrow Transplant 1997;19: 385\u2013387.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR30","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/S0140-6736(85)91784-2","volume":"1","author":"G Lucarelli","year":"1985","unstructured":"Lucarelli Get al. Marrow transplantation for thalassaemia following busulphan and cyclophosphamide.Lancet 1985;1: 1355\u20131357.","journal-title":"Lancet"},{"key":"BF02906128_CR31","first-page":"201","volume":"1","author":"JR Hobbs","year":"1986","unstructured":"Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJ, Williamson S. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children.Bone Marrow Transplant 1986;1: 201\u2013208.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR32","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(86)90477-0","volume":"2","author":"A Fischer","year":"1986","unstructured":"Fischer Aet al. Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968\u20131985.Lancet 1986;2: 1080\u20131084.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"BF02906128_CR33","first-page":"S5236","volume":"4","author":"GW Santos","year":"1989","unstructured":"Santos GW. Busulfan (Bu) and cyclophosphamide (Cy) for marrow transplantation.Bone Marrow Transplant 1989;4(Suppl 1): S5236-S5239.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR34","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1182\/blood.V64.4.852.852","volume":"64","author":"R Parkman","year":"1984","unstructured":"Parkman R, Rappeport JM, Hellman S, Lipton J, Smith Bet al. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.Blood 1984;64: 852\u2013857.","journal-title":"Blood"},{"key":"BF02906128_CR35","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/sj.bmt.1701248","volume":"21","author":"A Bonini","year":"1998","unstructured":"Bonini A, Bandini G, Rosti G, Rondelli D, Testoni Net al. Big BU\/CY is associated with a favorable long-term outcome in patients allotransplanted for chronic myelogenous leukemia in chronic phase.Bone Marrow Transplant 1998;21: 1085\u20131089.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00000421-199006000-00009","volume":"13","author":"R Brodsky","year":"1990","unstructured":"Brodsky R, Topolsky D, Crilley P, Bulova S, Brodsky I. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan-cyclophosphamide preparative regimen.Am J Clin Oncol 1990;13: 221\u2013225.","journal-title":"Am J Clin Oncol"},{"key":"BF02906128_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00694339","volume":"25","author":"LB Grochow","year":"1989","unstructured":"Grochow LBet al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation.Cancer Chemother Pharmacol 1989;25: 55\u201361.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR38","first-page":"197","volume":"10","author":"HM Shulman","year":"1992","unstructured":"Shulman HM, Hinterberger W. Hepatic Veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation.Bone Marrow Transplant 1992;10: 197\u2013214.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR39","first-page":"551","volume":"19","author":"MC Perry","year":"1992","unstructured":"Perry MC. Chemotherapeutic agents and hepatotoxicity.Semin Oncol 1992;19: 551\u2013565.","journal-title":"Semin Oncol"},{"key":"BF02906128_CR40","doi-asserted-by":"crossref","unstructured":"McDonald GBet al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.Ann Intern Med 1993;118.","DOI":"10.7326\/0003-4819-118-4-199302150-00003"},{"key":"BF02906128_CR41","doi-asserted-by":"publisher","first-page":"881","DOI":"10.7326\/0003-4819-112-11-881_1","volume":"112","author":"G Vassal","year":"1990","unstructured":"Vassal G, Hartmann O, Benhamou E. Busulfan and veno-occlusive disease of the liver [letter].Ann Intern Med 1990;112: 881.","journal-title":"Ann Intern Med"},{"key":"BF02906128_CR42","doi-asserted-by":"publisher","first-page":"173","DOI":"10.7326\/0003-4819-106-1-173_1","volume":"106","author":"RW Martell","year":"1987","unstructured":"Martell RW, Sher C, Jacobs P, Monteagudo F. High-dose busulfan and myoclonic epilepsy [letter].Ann Intern Med 1987;106: 173.","journal-title":"Ann Intern Med"},{"key":"BF02906128_CR43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.7326\/0003-4819-111-6-543_2","volume":"111","author":"A Sureda","year":"1989","unstructured":"Sureda A, Perez de Oteyza J, Garcia Larana J, Odriozola J. High-dose busulfan and seizures [letter].Ann Intern Med 1989;111: 543\u2013544.","journal-title":"Ann Intern Med"},{"key":"BF02906128_CR44","first-page":"385","volume":"2","author":"K Atkinson","year":"1987","unstructured":"Atkinson Ket al. Preparative regimens for marrow transplantation containing busulphan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis.Bone Marrow Transplant 1987;2: 385\u2013394.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR45","first-page":"347","volume":"1","author":"AE Thomas","year":"1987","unstructured":"Thomas AEet al. Haemorrhagic cystitis in bone marrow transplantation patients possible increased risk associated with prior busulphan therapy.Bone Marrow Transplant 1987;1: 347\u2013355.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR46","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood.V74.5.1507.1507","volume":"74","author":"DW Beelen","year":"1989","unstructured":"Beelen DWet al. Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia.Blood 1989;74: 1507\u20131516.","journal-title":"Blood"},{"key":"BF02906128_CR47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S0140-6736(84)91649-0","volume":"2","author":"RE Marcus","year":"1984","unstructured":"Marcus RE, Goldman JM. Convulsions due to high-dose busulphan [letter].Lancet 1984;2: 1463.","journal-title":"Lancet"},{"key":"BF02906128_CR48","first-page":"363","volume":"7","author":"R De La Camara","year":"1991","unstructured":"De La Camara R, Tomas JF, Figuera A, Berberana M, Fernandez-Ranada JM. High dose busulfan and seizures.Bone Marrow Transplant 1991;7: 363\u2013364.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR49","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S0378-4347(00)84861-6","volume":"277","author":"M Hassan","year":"1983","unstructured":"Hassan M, Ehrsson H. Gas Chromatographic determination of busulfan in plasma with electron-capture detection.J Chromatogr 1983;277: 374\u2013380.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0378-4347(00)83928-6","volume":"428","author":"G Vassal","year":"1988","unstructured":"Vassal G, Re M, Gouyette A. Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard.J Chromatogr 1988;428: 357\u2013361.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR51","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/0378-4347(87)80531-5","volume":"416","author":"WD Henner","year":"1987","unstructured":"Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography.J Chromatogr 1987;416: 426\u2013432.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0378-4347(92)80458-3","volume":"581","author":"S Pichini","year":"1992","unstructured":"Pichini Set al. High-performance liquid chromatographic-mass spectrometric assay of busulfan in serum and cerebrospinal fluid.J Chromatogr 1992;581: 143\u2013146.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF03189864","volume":"12","author":"M Hassan","year":"1987","unstructured":"Hassan M, Ehrsson H. Metabolism of 14C-busulfan in isolated perfused rat liver.Eur J Drug Metab Pharmacokinet 1987;12: 71\u201376.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"BF02906128_CR54","first-page":"399","volume":"15","author":"M Hassan","year":"1987","unstructured":"Hassan M, Ehrsson H. Urinary metabolites of busulfan in the rat.Drug Metab Dispos 1987;15: 399\u2013402.","journal-title":"Drug Metab Dispos"},{"key":"BF02906128_CR55","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00686397","volume":"30","author":"M Hassan","year":"1992","unstructured":"Hassan Met al. In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient.Cancer Chemother Pharmacol 1992;30: 81\u201385.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"BF02906128_CR56","first-page":"518","volume":"20","author":"LB Grochow","year":"1993","unstructured":"Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.Semin Oncon 1993;20(Suppl): 518\u2013525; 526.","journal-title":"Semin Oncon"},{"key":"BF02906128_CR57","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF00558081","volume":"36","author":"M Hassan","year":"1989","unstructured":"Hassan Met al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults.Eur J Clin Pharmacol 1989;36: 525\u2013530.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF02906128_CR58","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/BF00689702","volume":"28","author":"M Hassan","year":"1991","unstructured":"Hassan Met al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology.Cancern Chemother Pharmacol 1991;28: 130\u2013134.","journal-title":"Cancern Chemother Pharmacol"},{"key":"BF02906128_CR59","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood.V75.8.1723.1723","volume":"75","author":"LB Grochow","year":"1990","unstructured":"Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children.Blood 1990;75: 1723\u20131727.","journal-title":"Blood"},{"key":"BF02906128_CR60","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/BF00257448","volume":"24","author":"G Vassal","year":"1989","unstructured":"Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children.Cancer Chemother Pharmacol 1989;24: 386\u2013390.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR61","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1182\/blood.V82.3.1030.1030","volume":"82","author":"G Vassal","year":"1993","unstructured":"Vassal Get al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease.Blood 1993;82: 1030\u20131034.","journal-title":"Blood"},{"key":"BF02906128_CR62","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood.V84.7.2357.2357","volume":"84","author":"PJ Shaw","year":"1994","unstructured":"Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia.Blood 1994;84: 2357\u20132362.","journal-title":"Blood"},{"key":"BF02906128_CR63","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1700891","volume":"20","author":"DS Chattergoon","year":"1997","unstructured":"Chattergoon DSet al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children.Bone Marrow Transplant 1997:20: 347\u2013354.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/clpt.1993.108","volume":"54","author":"MB Regazzi","year":"1993","unstructured":"Regazzi MBet al. Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation.Clin Pharmacol Ther 1993;54: 45\u201352.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02906128_CR65","first-page":"843","volume":"18","author":"M Hassan","year":"1996","unstructured":"Hassan Met al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.Bone Marrow Transplant 1996;18: 843\u2013850.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR66","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","volume":"84","author":"M Hassan","year":"1994","unstructured":"Hassan Met al. Busulfan bioavailability.Blood 1994;84: 2144\u20132150.","journal-title":"Blood"},{"key":"BF02906128_CR67","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood.V79.9.2475.2475","volume":"79","author":"G Vassal","year":"1992","unstructured":"Vassal Get al. Is 600 mg\/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation?Blood 1992;79: 2475\u20132479.","journal-title":"Blood"},{"key":"BF02906128_CR68","first-page":"1534","volume":"53","author":"G Vassal","year":"1993","unstructured":"Vassal Get al. Chronopharmacology of high-dose busulfan in children.Cancer Res 1993;53: 1534\u20131537.","journal-title":"Cancer Res"},{"key":"BF02906128_CR69","first-page":"2083","volume":"16","author":"I Buggia","year":"1996","unstructured":"Buggia Iet al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo).Anticancer Res 1996;16: 2083\u20132088.","journal-title":"Anticancer Res"},{"key":"BF02906128_CR70","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00686213","volume":"33","author":"M Hassan","year":"1993","unstructured":"Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.Cancer Chemother Pharmacol 1993;33: 181\u2013186.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR71","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/00007890-198506000-00004","volume":"39","author":"BR Blazar","year":"1985","unstructured":"Blazar BRet al. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation.Transplantation 1985;39: 597\u2013603.","journal-title":"Transplantation"},{"key":"BF02906128_CR72","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00688324","volume":"37","author":"G Vassal","year":"1996","unstructured":"Vassal Get al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996;37: 247\u2013253.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR73","first-page":"759","volume":"14","author":"U Schuler","year":"1994","unstructured":"Schuler Uet al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?Bone Marrow Transplant 1994;14: 759\u2013765.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR74","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s002800050404","volume":"37","author":"HP Bhagwatwar","year":"1996","unstructured":"Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.Cancer Chemother Pharmacol 1996;37: 401\u2013408.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR75","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s002800050847","volume":"42","author":"M Hassan","year":"1998","unstructured":"Hassan Met al. Pharmacokinetics and distribution of liposomal busulfan in the rat: a new formulation for intravenous administration.Cancer Chemother Pharmacol 1998;42: 471\u2013478.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR76","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1182\/blood.V85.11.3247.bloodjournal85113247","volume":"85","author":"G Ehninger","year":"1995","unstructured":"Ehninger Get al. Use of a water soluble busulfan formulation pharmacokinetic studies in a canine model.Blood 1995;85: 3247\u20133249.","journal-title":"Blood"},{"key":"BF02906128_CR77","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/sj.bmt.1701458","volume":"22","author":"Z Hassan","year":"1998","unstructured":"Hassan Z, Nilsson C, Hassan M. Liposomal busulphan: bioavailability and effect on bone marrow in mice.Bone Marrow Transplant 1998;22: 913\u2013918.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR78","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0378-4347(88)80034-3","volume":"425","author":"TL Chen","year":"1988","unstructured":"Chen TL, Grochow LB, Hurowitz LA, Brundrett RB. Determination of busulfan in human plasma by gas chromaatography with electron-capture detection.J Chromatogr 1988;425: 303\u2013309.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR79","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF00685617","volume":"32","author":"L Embree","year":"1993","unstructured":"Embree Let al. Gas-chromatographic analysis of busulfan for therapeutic drug monitoring.Cancer Chemother Pharmacol 1993;32: 137\u2013142.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR80","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/jps.2600721024","volume":"72","author":"H Ehrsson","year":"1983","unstructured":"Ehrsson H, Hassan M. Determination of busulfan in plasma by GC-MS with selected-ion monitoring.J Pharm Sci 1983;72: 1203\u20131205.","journal-title":"J Pharm Sci"},{"key":"BF02906128_CR81","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","volume":"20","author":"JT Slattery","year":"1998","unstructured":"Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation.Ther Drug Monit 1998;20: 543\u2013549.","journal-title":"Ther Drug Monit"},{"key":"BF02906128_CR82","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0378-4347(00)82386-5","volume":"528","author":"AG Kazemifard","year":"1990","unstructured":"Kazemifard AG, Morgan DJ. Determination of busulfan in plasma by high-performance liquid chromatography.J Chromatogr 1990;528: 274\u2013276.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR83","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0378-4347(00)83794-9","volume":"532","author":"JJ MacKichan","year":"1990","unstructured":"MacKichan JJ, Bechtel TP. Quantitation of busulfan in plasma by high-performance liquid chromatography.J Chromatogr 1990;532: 424\u2013428.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR84","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0378-4347(00)83795-0","volume":"532","author":"J Blanz","year":"1990","unstructured":"Blanz J, Rosenfeld C, Proksch B, Ehninger G, Zeller KP. Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis.J Chromatogr 1990;532: 429\u2013437.","journal-title":"J Chromatogr"},{"key":"BF02906128_CR85","first-page":"713","volume":"19","author":"M Nadkarni","year":"1959","unstructured":"Nadkarni M, Trams E, Smith P. Preliminary studies on the distribution and fate of TEM, TEPA, and Myleran in the human.Cancer Res 1959;19: 713.","journal-title":"Cancer Res"},{"key":"BF02906128_CR86","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0006-2952(59)90052-8","volume":"2","author":"E Trams","year":"1959","unstructured":"Trams E, Nadkarni M, deQuattro V, Maengwyn-Davies G, Smith P. Dimethanesulphonoxybutane (Myleran), preliminary studies on distribution and metabolic fate in the rat.Biochem Pharmacol 1959;2: 7.","journal-title":"Biochem Pharmacol"},{"key":"BF02906128_CR87","first-page":"266","volume":"73","author":"H Vodopick","year":"1969","unstructured":"Vodopick H, Hamilton HE, Jackson HL, Peng CT, Sheets RF. Metabolic fate of tritiated busulfan in man.J Lab Clin Med 1969;73: 266\u2013276.","journal-title":"J Lab Clin Med"},{"key":"BF02906128_CR88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/clpt.1983.134","volume":"34","author":"H Ehrsson","year":"1983","unstructured":"Ehrsson H, Hassan M, Ehrnebo M, Beran M. Busulfan kinetics.Clin Pharmacol Ther 1983;34: 86\u201389.","journal-title":"Clin Pharmacol Ther"},{"key":"BF02906128_CR89","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.bmt.1701322","volume":"22","author":"US Schuler","year":"1998","unstructured":"Schuler USet al. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.Bone Marrow Transplant 1998;22: 241\u2013244.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR90","first-page":"2363","volume":"14","author":"G Vassal","year":"1994","unstructured":"Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).Anticancer Res 1994;14: 2363\u20132370.","journal-title":"Anticancer Res"},{"key":"BF02906128_CR91","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/BF03190094","volume":"13","author":"M Hassan","year":"1988","unstructured":"Hassan M, Ehrsson H, Wallin I, Eksborg S. Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.Eur J Drug Metab Pharmacokinet 1988;13: 301\u2013305.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"BF02906128_CR92","first-page":"113","volume":"4","author":"M Hassan","year":"1989","unstructured":"Hassan Met al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy.Bone Marrow Transplant 1989;4: 113\u2013114.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR93","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/j.2042-7158.1984.tb04847.x","volume":"36","author":"H Ehrsson","year":"1984","unstructured":"Ehrsson H, Hassan M. Binding of busulfan to plasma proteins and blood cells.J Pharm Pharmacol 1984;36: 694\u2013696.","journal-title":"J Pharm Pharmacol"},{"key":"BF02906128_CR94","first-page":"227","volume":"4","author":"C Kalifa","year":"1992","unstructured":"Kalifa Cet al. high-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.Bone Marrow Transplant 1992;4: 227\u2013233.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR95","first-page":"241","volume":"19","author":"PM Belanger","year":"1991","unstructured":"Belanger PM, Desgagne M, Bruguerolle B. Temporal variations in microsomal lipid peroxidation and in glutathione concentration of rat liver.Drug Metab Dispos 1991;19: 241\u2013244.","journal-title":"Drug Metab Dispos"},{"key":"BF02906128_CR96","first-page":"386","volume":"13","author":"PM Belanger","year":"1985","unstructured":"Belanger PM, Lalande M, Labrecque G, Dore FM. Diurnal variations in the transferases and hydrolases involved in glucuronide and sulfate conjugation of rat liver.Drug Metab Dispos 1985;13: 386\u2013389.","journal-title":"Drug Metab Dispos"},{"key":"BF02906128_CR97","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1016\/0006-2952(71)90100-6","volume":"20","author":"A Jori","year":"1971","unstructured":"Jori A, Di Salle E, Santini V. Daily rhythmic variation and liver drug metabolism in rats.Biochem Pharmacol 1971;20: 2965\u20132969.","journal-title":"Biochem Pharmacol"},{"key":"BF02906128_CR98","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/BF00685717","volume":"27","author":"WE Fitzsimmons","year":"1990","unstructured":"Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity.Cancer Chemother Pharmacol 1990;27: 226\u2013228.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF02906128_CR99","doi-asserted-by":"publisher","first-page":"552","DOI":"10.7326\/0003-4819-112-7-552_2","volume":"112","author":"WE Fitzsimmons","year":"1990","unstructured":"Fitzsimmons WE, Ghalie R, Kaizer H. Anticonvulsants and busulfan [letter].Ann Intern Med 1990;112: 552\u2013553.","journal-title":"Ann Intern Med"},{"key":"BF02906128_CR100","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.7326\/0003-4819-111-12-1049_2","volume":"111","author":"AP Grigg","year":"1990","unstructured":"Grigg AP, Shepherd JD, Phillips GL. Busulphan and phenytoin [letter].Ann Intern Med 1990;111: 1049\u20131050.","journal-title":"Ann Intern Med"},{"key":"BF02906128_CR101","first-page":"147","volume":"9","author":"P Tiberghien","year":"1992","unstructured":"Tiberghien P, Flesch M, Paintaud G, Cahn JY. More on high-dose busulfan and seizure prophylaxis [letter].Bone Marrow Transplant 1992;9: 147.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR102","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0006-2952(61)90133-2","volume":"6","author":"J Roberts","year":"1961","unstructured":"Roberts J, Warwick G. The mode of action of alkylating agents III: The formation of 3-hydroxy tetrahydrothiophene-1\u22361-dioxide from 1\u22364-dimethanesulphonyloxybutane (Myleran), S-\u03b2-L-alanyltetrahydrothiophenium mesylate, tetrahydrothiophene and tetrahydrothiophene-1\u22361-dioxide in the rat, rabbit and mouse.Biochem Pharmacol 1961;6: 217.","journal-title":"Biochem Pharmacol"},{"key":"BF02906128_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60008-1","volume-title":"The chemistry of cytotoxic alkylating agents","author":"W Ross","year":"1953","unstructured":"Ross W.The chemistry of cytotoxic alkylating agents. New York Academic Press; 1953."},{"key":"BF02906128_CR104","first-page":"101","volume":"2","author":"CD Dunn","year":"1974","unstructured":"Dunn CD. The chemical and biological properties of busulphan (Myleran).Exp Hematol 1974;2 101\u2013117.","journal-title":"Exp Hematol"},{"key":"BF02906128_CR105","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/0006-291X(85)91687-0","volume":"128","author":"DH Marchand","year":"1985","unstructured":"Marchand DH, Abdel-Monem KK. Glutathione S-transferases catalyzed conjugation of 1,4-disubstituted butanes with glutathione in vitro.Biochem Biophys Res Commun 1985;128: 360\u2013367.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF02906128_CR106","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0731-7085(86)80027-9","volume":"4","author":"M EH Hassan","year":"1986","unstructured":"Hassan M EH. Degradation of busulfan in aqueous solution.J Pharm Biomed Anal 1986;4: 95.","journal-title":"J Pharm Biomed Anal"},{"key":"BF02906128_CR107","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/jps.2600620634","volume":"62","author":"PW Feit","year":"1973","unstructured":"Feit PW, Rastrup-Andersen N. 4-Methanesulfonyloxybutanol: hydrolysis of busulfan.J Pharm Sci 1973;62: 1007\u20131008.","journal-title":"J Pharm Sci"},{"key":"BF02906128_CR108","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3109\/00498258609043502","volume":"16","author":"W Onkenhout","year":"1986","unstructured":"Onkenhout Wet al. Identification and quantitative determination of four different mercapturic acids formed from 1,3-dibromopropane and its 1,1,3,3-tetradeutero analogue by the rat.Xenobiotica 1986;16: 21\u201333.","journal-title":"Xenobiotica"},{"key":"BF02906128_CR109","first-page":"3678","volume":"56","author":"JP Gibbs","year":"1996","unstructured":"Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases.Cancer Res 1996;56: 3678\u20133681.","journal-title":"Cancer Res"},{"key":"BF02906128_CR110","first-page":"52","volume":"26","author":"JP Gibbs","year":"1998","unstructured":"Gibbs JP, Yang JS, Slattery JT. Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro.Drug Metab Dispos 1998;26: 52\u201355.","journal-title":"Drug Metab Dispos"},{"key":"BF02906128_CR111","first-page":"5509","volume":"57","author":"Jp Gibbs","year":"1997","unstructured":"Gibbs Jp, Murray G, Risler L, Chien JY, Dev R, Slatery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.Cancer Res 1997;57: 5509\u20135516.","journal-title":"Cancer Res"},{"key":"BF02906128_CR112","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJet al. Venoocclusive disease of the liver following bone marrow transplantation.Transplantation 1987;44: 778\u2013783.","journal-title":"Transplantation"},{"key":"BF02906128_CR113","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SPet al. Association of busulfan area under the curve with veno-occlusive disease following BMT.Bone Marrow Transplant 1996;17: 225\u2013230.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR114","first-page":"135","volume":"10","author":"V Meresse","year":"1992","unstructured":"Meresse Vet al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children.Bone Marrow Transplant 1992;10: 135\u2013141.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR115","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.bmt.1700994","volume":"20","author":"P Ljungman","year":"1997","unstructured":"Ljungman P, Hassan M, Bekassy, AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.Bone Marrow Transplant 1997;20: 909\u2013913.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR116","first-page":"869","volume":"15","author":"P Ljungman","year":"1995","unstructured":"Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants.Bone Marrow Transplant 1995;15: 869\u2013871.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR117","first-page":"6203","volume":"50","author":"G Vassal","year":"1990","unstructured":"Vassal Get al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study.Cancer Res 1990;50: 6203\u20136207.","journal-title":"Cancer Res"},{"key":"BF02906128_CR118","first-page":"199","volume":"9","author":"AM Yeager","year":"1992","unstructured":"Yeager AM, Shinn C, Farmer ER, Eingard JR, Yeager MJ. Growth retardation and depigmentation of hair after high-dose busulfan and congenic hematopoietic cenn transplantation in mice.Bone Marrow Transplant 1992;9: 199\u2013204.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR119","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1182\/blood.V79.4.1068.bloodjournal7941068","volume":"79","author":"JR Wingard","year":"1992","unstructured":"Wingard JRet al. Growth in children after bone marrow transplantation: busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation.Blood 1992;79: 1068\u20131073.","journal-title":"Blood"},{"key":"BF02906128_CR120","first-page":"244","volume":"28","author":"JE Sanders","year":"1991","unstructured":"Sanders JE. The impact of marrow transplant preparative regimens on subsequent growth and development. The Seattle Marrow Transplant Team.Semin Hematol 1991;28: 244\u2013249.","journal-title":"Semin Hematol"},{"key":"BF02906128_CR121","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/sj.bmt.1701244","volume":"21","author":"N Hirabayashi","year":"1998","unstructured":"Hirabayashi Net al. Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia.Bone Marrow Transplant 1998;21: 1079\u20131083.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR122","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1016\/S0959-8049(97)00227-X","volume":"33","author":"O Hartmann","year":"1997","unstructured":"Hartmann Oet al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation.Eur J Cancer 1997;33: 2126\u20132129.","journal-title":"Eur J Cancer"},{"key":"BF02906128_CR123","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/sj.bmt.1700820","volume":"19","author":"WI Bensinger","year":"1997","unstructured":"Bensinger WIet al. High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast cancer.Bone Marrow Transplant 1997;19: 1183\u20131189.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR124","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/sj.bmt.1701101","volume":"21","author":"CH Weaver","year":"1998","unstructured":"Weaver CHet al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin\u2019s lymphoma.Bone Marrow Transplant 1998;21: 383\u2013389.","journal-title":"Bone Marrow Transplant"},{"key":"BF02906128_CR125","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1365-2141.1991.tb08621.x","volume":"77","author":"M Morgan","year":"1991","unstructured":"Morgan Met al. The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation.Br J Haematol 1991;77: 529\u2013534.","journal-title":"Br J Haematol"},{"key":"BF02906128_CR126","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood.V79.10.2578.bloodjournal79102578","volume":"79","author":"D Blaise","year":"1992","unstructured":"Blaise Det al. Allogeneic bone marrow transplantation for acute myeloid lleukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d Etudes de la Greffe de Moelle Osseuse.Blood 1992;79: 2578\u20132582","journal-title":"Blood"},{"key":"BF02906128_CR127","first-page":"1831","volume":"26","author":"O Ringden","year":"1994","unstructured":"Ringden Oet al. A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies.Transplant Proc 1994;26: 1831\u20131832.","journal-title":"Transplant Proc"},{"key":"BF02906128_CR128","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/blood.V83.9.2723.2723","volume":"83","author":"O Ringden","year":"1994","unstructured":"Ringden Oet al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group.Blood 1994;83: 2723\u20132730.","journal-title":"Blood"},{"key":"BF02906128_CR129","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/sj.bmt.1701071","volume":"21","author":"RI Lalisang","year":"1998","unstructured":"Lalisang RI, Hupperets PS, ten Haaft MA, Jansen RL, Schouten HC. High-dose chemotherapy with autologous bone marrow support as consolidation after standard-dose adjuvant therapy in primary breast cancer patients with seven or more involved axillary lymph nodes.Bone Marrow Transplant 1998;21: 243\u2013247.","journal-title":"Bone Marrow Transplant"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02906128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF02906128\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02906128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02906128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T02:14:08Z","timestamp":1702606448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF02906128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,9]]},"references-count":129,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,9]]}},"alternative-id":["BF02906128"],"URL":"https:\/\/doi.org\/10.1007\/bf02906128","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,9]]},"assertion":[{"value":"10 February 1999","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 1999","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 1999","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}